All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Lilly, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC View funders.
Alison J. Moskowitz, MD, is a medical oncologist at the Memorial Sloan Kettering Cancer Center, New York, US, and is the Clinical Director of the Lymphoma Service, with a focus on the treatment of patients with Hodgkin lymphoma, systemic T-cell lymphoma, and cutaneous T-cell lymphoma.
Dr Moskowitz completed her medical training at the Albert Einstein College of Medicine, New York, US, and completed her internal medicine residency and internship at Columbia University Irving Medical Center, New York, US. She then completed hematology and medical oncology fellowships at Memorial Sloan Kettering Cancer Center, New York, US, and Weill Cornell Medical Center, New York, US.
Dr Moskowitz is involved with multiple professional organizations and holds professional memberships with the American Medical Association (AMA), the American Society of Clinical Oncology (ASCO), and the American Society of Hematology (ASH). Dr Moskowitz has lectured and authored peer-reviewed articles on autologous stem cell transplantation, relapsed/refractory Hodgkin lymphoma, and T-cell lymphoma. In particular, she has co-authored over 100 articles and has been lead investigator or co-lead investigator for more than 25 clinical trials.